JP2002514611A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002514611A5 JP2002514611A5 JP2000548013A JP2000548013A JP2002514611A5 JP 2002514611 A5 JP2002514611 A5 JP 2002514611A5 JP 2000548013 A JP2000548013 A JP 2000548013A JP 2000548013 A JP2000548013 A JP 2000548013A JP 2002514611 A5 JP2002514611 A5 JP 2002514611A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- independently selected
- acid
- twenty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 38
- 125000000623 heterocyclic group Chemical group 0.000 description 33
- 229910052760 oxygen Inorganic materials 0.000 description 32
- 229910052717 sulfur Inorganic materials 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 27
- 125000005842 heteroatom Chemical group 0.000 description 26
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 24
- 229910052757 nitrogen Inorganic materials 0.000 description 24
- 229960003104 ornithine Drugs 0.000 description 24
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 22
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 22
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 20
- 239000004471 Glycine Substances 0.000 description 19
- DYCLHZPOADTVKK-UHFFFAOYSA-N 2-(2-azaniumyl-1,3-thiazol-4-yl)acetate Chemical compound NC1=NC(CC(O)=O)=CS1 DYCLHZPOADTVKK-UHFFFAOYSA-N 0.000 description 18
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 18
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 18
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 18
- 239000004472 Lysine Substances 0.000 description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 17
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 16
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 16
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 16
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 15
- 229930182832 D-phenylalanine Natural products 0.000 description 15
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 15
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 15
- 229960003767 alanine Drugs 0.000 description 15
- LRQKBLKVPFOOQJ-RXMQYKEDSA-N D-norleucine Chemical compound CCCC[C@@H](N)C(O)=O LRQKBLKVPFOOQJ-RXMQYKEDSA-N 0.000 description 14
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 14
- 229930182831 D-valine Natural products 0.000 description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 14
- 235000018977 lysine Nutrition 0.000 description 14
- 229960004441 tyrosine Drugs 0.000 description 14
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 229960004295 valine Drugs 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- OFYAYGJCPXRNBL-GFCCVEGCSA-N (2r)-2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(C[C@@H]([NH3+])C([O-])=O)=CC=CC2=C1 OFYAYGJCPXRNBL-GFCCVEGCSA-N 0.000 description 12
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 12
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- -1 biphenylglycine Chemical compound 0.000 description 12
- 229960000310 isoleucine Drugs 0.000 description 12
- 229960003136 leucine Drugs 0.000 description 12
- 229960001639 penicillamine Drugs 0.000 description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 10
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 9
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 9
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 9
- VVNCNSJFMMFHPL-GSVOUGTGSA-N L-penicillamine Chemical compound CC(C)(S)[C@H](N)C(O)=O VVNCNSJFMMFHPL-GSVOUGTGSA-N 0.000 description 9
- 229960004452 methionine Drugs 0.000 description 9
- 229960001153 serine Drugs 0.000 description 9
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 8
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 8
- AHLPHDHHMVZTML-SCSAIBSYSA-N D-Ornithine Chemical compound NCCC[C@@H](N)C(O)=O AHLPHDHHMVZTML-SCSAIBSYSA-N 0.000 description 8
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 8
- ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 8
- 229930182845 D-isoleucine Natural products 0.000 description 8
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 8
- 229930182819 D-leucine Natural products 0.000 description 8
- 229930195709 D-tyrosine Natural products 0.000 description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 8
- 235000004279 alanine Nutrition 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- ORQXBVXKBGUSBA-UHFFFAOYSA-N cyclohexyl D-alanine Natural products OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 8
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 8
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 description 8
- JTTHKOPSMAVJFE-SECBINFHSA-N (2r)-2-azaniumyl-4-phenylbutanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC1=CC=CC=C1 JTTHKOPSMAVJFE-SECBINFHSA-N 0.000 description 7
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 7
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 7
- 229930195711 D-Serine Natural products 0.000 description 7
- 125000000217 alkyl group Chemical group 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- NMDDZEVVQDPECF-LURJTMIESA-N (2s)-2,7-diaminoheptanoic acid Chemical compound NCCCCC[C@H](N)C(O)=O NMDDZEVVQDPECF-LURJTMIESA-N 0.000 description 6
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 6
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 6
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 description 6
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 6
- 229930182818 D-methionine Natural products 0.000 description 6
- 229930195710 D‐cysteine Natural products 0.000 description 6
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 6
- GHSJKUNUIHUPDF-BYPYZUCNSA-N L-thialysine Chemical compound NCCSC[C@H](N)C(O)=O GHSJKUNUIHUPDF-BYPYZUCNSA-N 0.000 description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
- 235000013477 citrulline Nutrition 0.000 description 6
- 229960002173 citrulline Drugs 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 229960002433 cysteine Drugs 0.000 description 6
- 229960002449 glycine Drugs 0.000 description 6
- 229960003646 lysine Drugs 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 4
- 229930182844 L-isoleucine Natural products 0.000 description 4
- 235000019454 L-leucine Nutrition 0.000 description 4
- 239000004395 L-leucine Substances 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 229960005190 phenylalanine Drugs 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 3
- PZQBRYFKLBDVPE-JUUVMNCLSA-N C[C@H](Nc1cccs1)C(O)=O.N[C@@H](Cc1ccccc1)C(O)=O Chemical compound C[C@H](Nc1cccs1)C(O)=O.N[C@@H](Cc1ccccc1)C(O)=O PZQBRYFKLBDVPE-JUUVMNCLSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 3
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- 229930195722 L-methionine Natural products 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 3
- NVHPXYIRNJFKTE-HAGHYFMRSA-N 2-[(2s,5r,8s,11s)-8-(4-aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1CC1=CC=CC=C1 NVHPXYIRNJFKTE-HAGHYFMRSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical group O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 0 *1NIII*1 Chemical compound *1NIII*1 0.000 description 1
- 125000005865 C2-C10alkynyl group Chemical group 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 150000003668 tyrosines Chemical group 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8015098P | 1998-03-31 | 1998-03-31 | |
| US60/080,150 | 1998-03-31 | ||
| US11271598P | 1998-12-18 | 1998-12-18 | |
| US60/112,715 | 1998-12-18 | ||
| PCT/US1999/006826 WO1999058162A2 (en) | 1998-03-31 | 1999-03-29 | Pharmaceuticals for the imaging of angiogenic disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002514611A JP2002514611A (ja) | 2002-05-21 |
| JP2002514611A5 true JP2002514611A5 (enExample) | 2009-06-25 |
| JP4487019B2 JP4487019B2 (ja) | 2010-06-23 |
Family
ID=26763137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548013A Expired - Fee Related JP4487019B2 (ja) | 1998-03-31 | 1999-03-29 | 血管新生疾患を画像化するための薬剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20020001566A1 (enExample) |
| EP (1) | EP1068224B1 (enExample) |
| JP (1) | JP4487019B2 (enExample) |
| KR (1) | KR20010042288A (enExample) |
| CN (1) | CN1295578A (enExample) |
| AR (1) | AR020586A1 (enExample) |
| AT (1) | ATE295369T1 (enExample) |
| AU (1) | AU5541799A (enExample) |
| BR (1) | BR9909420A (enExample) |
| CA (1) | CA2324555A1 (enExample) |
| DE (1) | DE69925262T2 (enExample) |
| EA (1) | EA200001007A1 (enExample) |
| EE (1) | EE200000574A (enExample) |
| ES (1) | ES2241313T3 (enExample) |
| HU (1) | HUP0101468A2 (enExample) |
| IL (1) | IL138093A0 (enExample) |
| NO (1) | NO20004917L (enExample) |
| PL (1) | PL343804A1 (enExample) |
| SK (1) | SK13952000A3 (enExample) |
| WO (1) | WO1999058162A2 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6749853B1 (en) * | 1992-03-05 | 2004-06-15 | Board Of Regents, The University Of Texas System | Combined methods and compositions for coagulation and tumor treatment |
| US5965132A (en) * | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| US6794518B1 (en) * | 1998-12-18 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| EP1281068B1 (en) * | 2000-05-08 | 2008-03-26 | TTP LabTech Ltd | Microphysiometer |
| EP1289565B1 (en) | 2000-06-02 | 2015-04-22 | Bracco Suisse SA | Compounds for targeting endothelial cells |
| US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
| AU2001268710A1 (en) * | 2000-06-21 | 2002-01-02 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| AU2001270025B2 (en) * | 2000-06-21 | 2005-08-18 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| US20020122768A1 (en) * | 2000-07-06 | 2002-09-05 | Shuang Liu | Stable radiopharmaceutical compositions and methods for preparation thereof |
| JP2005506952A (ja) * | 2000-11-27 | 2005-03-10 | ブリストル−マイヤーズ・スクイブ・メディカル・イメージング・インコーポレイテッド | 心臓潅流およびビトロネクチンレセプター標的造影剤の同時造影 |
| TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| US7271180B2 (en) * | 2001-01-23 | 2007-09-18 | Wyeth | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| DE60231801D1 (de) | 2001-04-23 | 2009-05-14 | Mallinckrodt Inc | Tc und re markierte radioaktive glycosylierte octreotid-derivate |
| JP2004537573A (ja) * | 2001-08-08 | 2004-12-16 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 心臓灌流およびビトロネクチン受容体を標的とするイメージング剤の同時イメージング |
| KR101159061B1 (ko) | 2001-10-22 | 2012-06-22 | 더 스크립스 리서치 인스티튜트 | 항체 표적화 화합물 |
| US7279150B2 (en) | 2002-01-24 | 2007-10-09 | Barnes-Jewish Hospital | Chelating agents with lipophilic carriers |
| JP4731117B2 (ja) | 2002-01-24 | 2011-07-20 | バーンズ−ジューイッシュ ホスピタル | インテグリン標的イメージング剤 |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| ES2506142T3 (es) * | 2002-03-01 | 2014-10-13 | Dyax Corp. | Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico |
| US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
| US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
| US7985402B2 (en) | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
| US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| US7666979B2 (en) * | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
| US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
| US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
| AU2003235489A1 (en) * | 2002-05-08 | 2003-11-11 | Tom Mcneil | High efficiency solid-state light source and methods of use and manufacture |
| US6961607B2 (en) * | 2002-07-31 | 2005-11-01 | Uzgiris Egidijus E | Method for assessing myocardial angiogenesis |
| US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
| US20040122354A1 (en) * | 2002-09-05 | 2004-06-24 | Semba Charles P. | Infusion catheter having an integrated doppler transducer |
| US20040047917A1 (en) * | 2002-09-06 | 2004-03-11 | Stephen Wilson | Drug delivery and targeting with vitamin B12 conjugates |
| CA2499496C (fr) * | 2002-09-19 | 2012-04-24 | Centre National De La Recherche Scientifique - Cnrs | Synthese et caracterisation de nouveaux systemes de guidage et de vectorisation de molecules d'interet therapeutique vers des cellules cibles |
| WO2004069281A1 (en) * | 2003-01-30 | 2004-08-19 | The General Hospital Corporation | Bifunctional molecules comprising at least one integrin-binding and their use in imaging and therapy of angiogenesis and related disorders |
| EP2949658B1 (en) | 2003-03-03 | 2018-08-08 | Dyax Corp. | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
| MXPA05012109A (es) * | 2003-05-12 | 2006-02-08 | Bristol Myers Squibb Pharma Co | Compuestos antagonistas del receptor de vitronectina y su uso en la preparacion de radiofarmaceuticos. |
| AU2004263136A1 (en) * | 2003-08-08 | 2005-02-17 | Barnes-Jewish Hospital | Emulsion particles for imaging and therapy and methods of use thereof |
| US20050112064A1 (en) * | 2003-08-12 | 2005-05-26 | Sonya Franklin | DNA-dependent MRI contrast agents |
| EP1711203A4 (en) * | 2004-01-16 | 2007-06-13 | Barnes Jewish Hospital | TARGETED ATHEROSCLEROSIS TREATMENT |
| WO2005082912A1 (en) * | 2004-02-23 | 2005-09-09 | Dow Global Technologies Inc | Aqueous-based adhesive for bonding low surface energy substrates |
| US7504088B2 (en) | 2004-06-09 | 2009-03-17 | Kereos, Inc. | Lipophilic derivatives of chelate monoamides |
| DE602005000853D1 (de) * | 2004-07-02 | 2007-05-24 | Vivactis Nv | Messung der Wärme erzeugt durch einen chemischen oder biologischen Prozess. |
| EP1861127A1 (en) * | 2005-03-10 | 2007-12-05 | Bayer Schering Pharma Aktiengesellschaft | Chelators for radioactively labeled conjugates comprising a stabilizing sidechain |
| US20090131327A1 (en) * | 2005-04-29 | 2009-05-21 | Patrick Doherty | Nogo receptor functional motifs and peptide mimetics related thereto and methods of using the same |
| JP2009512443A (ja) * | 2005-10-20 | 2009-03-26 | ザ スクリップス リサーチ インスチチュート | 免疫染色及び免疫標的化のためのＦｃ標識化 |
| US20070140973A1 (en) * | 2005-12-15 | 2007-06-21 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardium perfusion imaging |
| EP2019667A4 (en) * | 2006-04-27 | 2012-08-22 | Barnes Jewish Hospital | DETECTION AND IMAGING OF TARGET TISSUE |
| US20080138288A1 (en) * | 2006-09-29 | 2008-06-12 | Washington University | Combinations for treatment of neovasculature |
| EP2107887A1 (en) * | 2006-12-08 | 2009-10-14 | Molecular Image Inc. | Methods for diagnosis and monitoring of neurologic diseases using magnetic resonance methods |
| US8194963B2 (en) * | 2008-03-10 | 2012-06-05 | Siemens Medical Solutions Usa, Inc. | Efficient estimator of pharmacokinetic parameters in breast MRI |
| CA2727803C (en) | 2008-05-13 | 2013-03-12 | University Of Kansas | Metal abstraction peptide (map) tag and associated methods |
| US20100178245A1 (en) * | 2009-01-13 | 2010-07-15 | Arnsdorf Morton F | Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| CN101659694B (zh) * | 2009-05-06 | 2012-12-12 | 河北科技大学 | 抗肿瘤环五肽化合物及其制备方法 |
| WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
| AU2014241182A1 (en) * | 2013-03-27 | 2015-09-24 | Theranos Ip Company, Llc | Biological sample processing |
| JP6542197B2 (ja) * | 2013-04-12 | 2019-07-10 | エヴォックス・セラピューティクス・リミテッド | 治療的送達小胞 |
| DE102013113156A1 (de) * | 2013-11-28 | 2015-05-28 | Freie Universität Berlin | Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese |
| KR102548998B1 (ko) * | 2020-03-31 | 2023-06-29 | 재단법인 아산사회복지재단 | 혈전영상을 위한 방사성의약품 및 조성물 |
| US12377166B2 (en) * | 2021-08-26 | 2025-08-05 | University Of Washington | Iron oxide nanoparticle for targeted chemo-immunotherapy |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| DE3360633D1 (en) | 1982-02-12 | 1985-10-03 | Unitika Ltd | Anti-cancer device |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US5135736A (en) | 1988-08-15 | 1992-08-04 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| IL91933A (en) | 1988-10-11 | 1994-12-29 | Univ Southern California | Their immuno-bracelet and isophiles which are beneficial in increasing vascular permeability or blood supply to tumor or otherwise damaged tissue |
| ATE142505T1 (de) | 1988-11-14 | 1996-09-15 | Brigham & Womens Hospital | Antikörper, spezifisch gegen elam-1 sowie deren verwendung |
| US5376356A (en) | 1989-03-14 | 1994-12-27 | Neorx Corporation | Imaging tissue sites of inflammation |
| JPH04502769A (ja) | 1989-04-10 | 1992-05-21 | オンコーゲン リミテッド パートナーシップ | オンコスタチンｍを使用したヒト内皮細胞増殖およびエフェクター機能の制御法 |
| US5395609A (en) | 1989-06-19 | 1995-03-07 | Antisoma Limited | Synthetic peptides for use in tumor detection |
| DE69018226T2 (de) | 1989-07-20 | 1995-09-21 | Sandoz-Patent-Gmbh, 79539 Loerrach | Markierte polypeptidderivate. |
| IN172208B (enExample) | 1990-04-02 | 1993-05-01 | Sint Sa | |
| WO1993008210A1 (en) | 1991-10-18 | 1993-04-29 | Beth Israel Hospital Association | Vascular permeability factor targeted compounds |
| US5965132A (en) | 1992-03-05 | 1999-10-12 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| CN1701814A (zh) | 1992-11-13 | 2005-11-30 | 马克斯普朗克科学促进协会 | 作为血管内皮生长因子受体的f1k－1 |
| US5342757A (en) | 1992-11-13 | 1994-08-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which specifically binds to endosialin, a 165 Kd glycoprotein found on tumor vascular endothelium, and uses thereof |
| DE4301871A1 (de) | 1993-01-13 | 1994-07-14 | Diagnostikforschung Inst | Neue Mittel zur Diagnose von Gefäßerkrankungen |
| US5744120A (en) | 1993-03-30 | 1998-04-28 | The Dupont Merick Pharmaceutical Company | Ternary radiopharmaceutical complexes |
| DE4311023C2 (de) | 1993-03-31 | 1996-05-02 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
| JPH09500140A (ja) | 1993-07-19 | 1997-01-07 | レゾリューション・ファーマスーティカルズ・インコーポレーテッド | Ｎ▲下３▼ｓ立体配置を有するヒドラジノ型放射性核種キレート形成剤 |
| US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
| JPH10504807A (ja) | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
| HU220347B (hu) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Készítmény az érrendszer specifikus koagulálásához |
| AU702487B2 (en) | 1995-08-30 | 1999-02-25 | G.D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| DE19536785A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ S¶2¶NY für radioaktive Isotope |
| DE19536781A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle sulfidhaltige Sulfonamid-Chelatbildner vom Typ XSNS für radioaktive Isotope |
| DE69628731T3 (de) * | 1995-11-01 | 2012-09-20 | Bracco Suisse S.A. | Gezielte magnetisch markierte molekularmarkersysteme als nmr-bilderzeugungsmittel |
| CN1202161A (zh) | 1995-11-14 | 1998-12-16 | 杜邦麦克药品公司 | 作为金属蛋白酶抑制剂的新的大环化合物 |
| US6331285B1 (en) * | 1996-06-05 | 2001-12-18 | Palatin Technologies, Inc. | Structurally determined cyclic metallo-constructs and applications |
| ZA978758B (en) * | 1996-10-02 | 1999-03-30 | Du Pont Merck Pharma | Technetium-99m-labeled chelator incorporated cyclic peptides that bind to the GPIIb/IIIa receptor as imaging agents |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| WO1998016256A1 (en) * | 1996-10-16 | 1998-04-23 | The Burnham Institute | Magnetic resonance imaging of thrombi |
| WO1998018497A2 (en) | 1996-10-28 | 1998-05-07 | Nycomed Imaging As | Contrast agents |
| GB9708265D0 (en) | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| DE19725368A1 (de) * | 1997-06-16 | 1998-12-17 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren und deren Verwendung für bildgebende Verfahren |
| AU9477398A (en) * | 1997-09-10 | 1999-03-29 | Burnham Institute, The | Methods of identifying molecules that home to angiogenic vasculature in tumors |
| WO1999040947A2 (en) * | 1998-02-11 | 1999-08-19 | Resolution Pharmaceuticals Inc. | Angiogenesis targeting molecules |
| WO2000006169A1 (en) | 1998-07-29 | 2000-02-10 | Merck & Co., Inc. | Integrin receptor antagonists |
-
1999
- 1999-03-29 KR KR1020007010831A patent/KR20010042288A/ko not_active Withdrawn
- 1999-03-29 EP EP99941944A patent/EP1068224B1/en not_active Expired - Lifetime
- 1999-03-29 HU HU0101468A patent/HUP0101468A2/hu unknown
- 1999-03-29 CN CN99804710A patent/CN1295578A/zh active Pending
- 1999-03-29 PL PL99343804A patent/PL343804A1/xx unknown
- 1999-03-29 AU AU55417/99A patent/AU5541799A/en not_active Abandoned
- 1999-03-29 WO PCT/US1999/006826 patent/WO1999058162A2/en not_active Ceased
- 1999-03-29 EE EEP200000574A patent/EE200000574A/xx unknown
- 1999-03-29 CA CA002324555A patent/CA2324555A1/en not_active Abandoned
- 1999-03-29 SK SK1395-2000A patent/SK13952000A3/sk unknown
- 1999-03-29 EA EA200001007A patent/EA200001007A1/ru unknown
- 1999-03-29 AT AT99941944T patent/ATE295369T1/de not_active IP Right Cessation
- 1999-03-29 ES ES99941944T patent/ES2241313T3/es not_active Expired - Lifetime
- 1999-03-29 JP JP2000548013A patent/JP4487019B2/ja not_active Expired - Fee Related
- 1999-03-29 BR BR9909420-7A patent/BR9909420A/pt not_active IP Right Cessation
- 1999-03-29 DE DE69925262T patent/DE69925262T2/de not_active Expired - Lifetime
- 1999-03-29 IL IL13809399A patent/IL138093A0/xx unknown
- 1999-03-30 AR ARP990101448A patent/AR020586A1/es not_active Application Discontinuation
- 1999-03-30 US US09/281,474 patent/US20020001566A1/en not_active Abandoned
- 1999-03-30 US US09/281,207 patent/US6322770B1/en not_active Expired - Fee Related
-
2000
- 2000-09-29 NO NO20004917A patent/NO20004917L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002514611A5 (enExample) | ||
| US7635751B2 (en) | Peptides having ligand activities on APJ that is an orphan G protein-coupled receptor, and use thereof | |
| TWI776821B (zh) | α-V β-6整合素配位子 | |
| RU2012120905A (ru) | СОЕДИНЕНИЯ, НАПРАВЛЕННЫЕ НА Gadd45β, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ НАРУШЕНИЯ, АССОЦИИРОВАННЫХ С ПАТОЛОГИЧЕСКОЙ ПОВЫШЕННОЙ ЭКСПРЕССИЕЙ И/ИЛИ АКТИВНОСТЬЮ Gadd45β И/ИЛИ ПАТОЛОГИЧЕСКОЙ АКТИВАЦИЕЙ ПУТИ NF-кВ | |
| JPH09512806A (ja) | 新規なアミノ酸誘導体、その製造方法及びこれらの化合物を含む医薬組成物（ｉｉ） | |
| JP2013508346A5 (enExample) | ||
| JP2004537581A5 (enExample) | ||
| JP2013533864A5 (enExample) | ||
| FI76558C (fi) | Foerfarande foer framstaellning av en vid blodtrycksjukdom anvaendbar inhibition foer angiotensinomvandlande enzym. | |
| JP2012512901A5 (enExample) | ||
| JP2008518978A5 (enExample) | ||
| RU2001127246A (ru) | Соединения-модуляторы пептида β-амилоида (варианты), фармацевтическая композиция, способ предотвращения агрегации природных пептидов β-амилоида, способ обнаружения присутствия или отсутствия природных пептидов β-амилоида в биологическом образце и способ лечения заболевания у субъекта, ассоциированного с β-амилоидозом | |
| JP2007537989A (ja) | 安定化ペプチド | |
| JP2007504144A5 (enExample) | ||
| JP2016515999A5 (enExample) | ||
| WO2009003284A8 (en) | Novel peptides, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same | |
| AU2001264679A1 (en) | Synthesis of n-(n-(3,3-dimethylbutyl)-l-alpha-aspartyl)-l-phenylalanine 1-methylester using oxazolidinone derivatives | |
| JP2017518363A5 (enExample) | ||
| JP2837352B2 (ja) | 胃腸運動活性を抑制するモチリン類似ポリペプチド | |
| US5795957A (en) | Polypeptide compounds containing D-2-alkyltryptophan capable of promoting the release of growth hormone | |
| JPS6136297A (ja) | カルボキシアルキルジペプチドを製造する方法 | |
| JP2006505555A5 (enExample) | ||
| JP2008520658A5 (enExample) | ||
| JP2006528208A5 (enExample) | ||
| JP2003522184A5 (enExample) |